Trial Profile

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of DCVAC/OvCa Added to Standard of Care in Patients With Relapsed Platinum-sensitive Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma

Status: Withdrawn prior to enrolment

Phase of Trial: Phase III

Latest Information Update: 29 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DCVAC OvCa (Primary)
Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Registrational; Therapeutic Use
Acronyms VITALIA
Sponsors SOTIO

06 Dec 2021 Planned primary completion date changed from 1 Jul 2027 to 1 Aug 2027.
06 Dec 2021 Planned initiation date changed from 1 Sep 2021 to 1 Aug 2021.
06 Dec 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com